# A Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GSK Vaccines Institute for Global Health (GVGH) Quadrivalent Pan-Salmonella Vaccine With and Without Alum in Healthy Young Adults

> **NCT07663032** · PHASE1 · RECRUITING · sponsor: **GlaxoSmithKline** · enrollment: 196 (estimated)

## Conditions studied

- Salmonella Infections

## Interventions

- **BIOLOGICAL:** Pan-Salmonella-with-Alum (Low dose) vaccine
- **BIOLOGICAL:** Pan-Salmonella-with-Alum (Full dose) vaccine
- **BIOLOGICAL:** Pan-Salmonella-without-Alum (Low dose) vaccine
- **BIOLOGICAL:** Pan-Salmonella-without-Alum (Full dose) vaccine
- **BIOLOGICAL:** Typhoid Vi conjugate vaccine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07663032
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-06-24
- **Primary completion:** 2027-11-14
- **Final completion:** 2027-11-14
- **Target enrollment:** 196 (ESTIMATED)
- **Last updated:** 2026-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07663032

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07663032, "A Study to Evaluate the Safety, Reactogenicity, and Immune Response of the GSK Vaccines Institute for Global Health (GVGH) Quadrivalent Pan-Salmonella Vaccine With and Without Alum in Healthy Young Adults". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07663032. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*